ANA ESCOBEDO: Open Payments
NPI 1912407578 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 35 payments from 15 companies in 2025. Trend: 2023 $467 · 2024 $891 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $177 |
| AstraZeneca Pharmaceuticals LP | 4 | $150 |
| PFIZER INC. | 3 | $73 |
| SANOFI PASTEUR INC. | 2 | $59 |
| Boston Scientific Corporation | 1 | $43 |
| Dexcom, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $28 |
| SHIELD THERAPEUTICS INC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
Products named: FARXIGA, Ozempic, PREVNAR 20, Wegovy, APOLLO ESG System, FLUZONE HIGH-DOSE, Dexcom G6 Transmitter, Veozah.
Industry payments across TX — which companies pay providers there.
